Pracinostat for AML update: follow-up analysis and Phase III trial
Description: Pracinostat is a histone deacetylase (HDAC) inhibitor that has demonstrated very promising efficacy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Here, Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, gives us an update on the follow-up analysis of the Phase II trial of the drug in combination with azacitidine in elderly patients with AML. Dr Garcia-Manero also discusses the Phase III trial of pracinostat for AML, which is currently recruiting. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Shared By : VJHemOnc
Posted on : 01/08/18
Added : 9 months ago